Daily Anesthesiology Research Analysis
AI-enabled perioperative care dominated today's anesthesiology-relevant literature. An implementation study in Nature Medicine showed that registry-trained AI risk stratification guiding personalized perioperative pathways reduced complications after colorectal cancer surgery. Complementing this, an explainable deep-learning model using preoperative 12‑lead ECG outperformed the RCRI for predicting perioperative cardiovascular events, and a randomized trial suggested continuous hypertonic saline
Summary
AI-enabled perioperative care dominated today's anesthesiology-relevant literature. An implementation study in Nature Medicine showed that registry-trained AI risk stratification guiding personalized perioperative pathways reduced complications after colorectal cancer surgery. Complementing this, an explainable deep-learning model using preoperative 12‑lead ECG outperformed the RCRI for predicting perioperative cardiovascular events, and a randomized trial suggested continuous hypertonic saline may improve brain relaxation and postoperative edema vs mannitol in supratentorial tumor surgery.
Research Themes
- AI-driven perioperative risk stratification and pathway personalization
- Explainable ECG-based deep learning for perioperative MACE prediction
- Hypertonic saline versus mannitol for brain relaxation in neurosurgery
Selected Articles
1. Clinical implementation of an AI-based prediction model for decision support for patients undergoing colorectal cancer surgery.
An AI model trained on 18,403 registry patients was implemented to personalize perioperative care by predicted 1-year mortality risk. In a before/after implementation, comprehensive complications (CCI>20) and medical complications were significantly reduced, and short-term modeling suggested cost-effectiveness.
Impact: Demonstrates real-world, scalable integration of AI for perioperative decision support with measurable outcome improvements. Provides a template for anesthesia-surgical services to deploy risk-adaptive pathways.
Clinical Implications: Institutions can adopt registry-trained AI to stratify risk and allocate perioperative resources (optimization, monitoring, infection prevention) according to predicted 1-year mortality, potentially reducing complications and costs. Multidisciplinary governance and monitoring for drift and equity are required.
Key Findings
- Validation AUROC for 1-year mortality prediction was 0.79.
- Personalized pathways reduced CCI>20 from 28.0% to 19.1% (adjusted OR 0.63; P=0.02).
- Medical complications decreased from 37.3% to 23.7% (OR 0.53; P<0.001) and modeling suggested cost-effectiveness.
Methodological Strengths
- Large-scale national registry development cohort with prospective clinical implementation.
- Clear, patient-important outcomes with risk-adaptive intervention intensity and before/after evaluation.
Limitations
- Nonrandomized before/after design is susceptible to secular trends and residual confounding.
- Implementation occurred at a single center; external generalizability and long-term durability need confirmation.
Future Directions: Cluster-randomized or stepped-wedge trials to confirm causal impact; fairness audits; integration with anesthesia information systems for automated, closed-loop perioperative pathways.
Adverse outcomes after elective cancer surgery are a main contributor to decreased survival, poorer oncological outcomes and increased healthcare costs. Identifying high-risk patients and selecting interventions according to individual risk profiles in the perioperative period in cancer surgery is a challenge. Using real-world data on 18,403 patients with colorectal cancer from Danish national registries and consecutive patients from a single center, we developed, validated and implemented an artificial-intelligence-based risk prediction model in clinical practice as a decision support tool for personalized perioperative treatment. Personalized treatment pathways were designed according to the predicted risk of 1-year mortality with the intensity of interventions increasing with the predicted risk. The developed model had an area under the receiver operating characteristic curve of 0.79 in the validation set. Results from the nonrandomized before/after cohort study showed an incidence proportion of the comprehensive complication index >20 of 19.1% in the personalized treatment group versus 28.0% in the standard-of-care group, adjusted odds ratio of 0.63 (95% confidence interval, 0.42-0.92; P = 0.02). The incidence of any medical complication was 23.7% in the personalized treatment group and 37.3% in the standard-of-care group; odds ratio of 0.53 (95% confidence interval, 0.36-0.76; P < 0.001). According to the short-term health economic modeling, personalized perioperative treatment was cost effective. The study demonstrates a fully scalable registry-based approach for using readily available data in an artificial-intelligence-based decision support pipeline in clinical practice. Our results indicate that this specific approach can be a cost-effective strategy to improve key surgical clinical outcomes.
2. Preoperative risk prediction of major cardiovascular events in noncardiac surgery using the 12-lead electrocardiogram: an explainable deep learning approach.
Using 37,081 surgical patients, a fusion deep-learning model combining preoperative 12‑lead ECG waveforms and routine clinical data markedly outperformed the RCRI in predicting perioperative MI, in-hospital mortality, and a composite outcome. Explainable counterfactuals identified ECG features (QRS prolongation, low voltage, ST depression) that drove risk.
Impact: Provides a scalable, explainable and automated risk tool using an already-available ECG signal, with clear superiority to a widely used clinical index.
Clinical Implications: Preoperative ECG-based deep learning can augment perioperative cardiovascular risk stratification, informing anesthesia monitoring intensity, hemodynamic targets, and disposition planning. External, prospective validation and workflow integration are needed before routine adoption.
Key Findings
- Fusion ECG+clinical model achieved AUROC 0.858 for in-hospital MI and 0.899 for in-hospital mortality.
- Outperformed ECG-only models and the RCRI (e.g., MI prediction P=0.001 vs RCRI).
- Explainability highlighted QRS prolongation, low-voltage complexes, and ST depression as risk-driving ECG patterns.
Methodological Strengths
- Large sample size with 10-fold cross-validation and formal comparison to a clinical benchmark (RCRI).
- Explainable AI via generative counterfactuals and multimodal data fusion.
Limitations
- Retrospective single-database study; potential dataset shift and generalizability concerns.
- Outcomes limited to in-hospital events and 30-day mortality for the composite; prospective impact on management not tested.
Future Directions: Prospective multicenter validation with clinical impact assessment, calibration drift monitoring, and integration into anesthesia information systems as a decision support module.
BACKGROUND: The Revised Cardiac Risk Index (RCRI) only modestly predicts major adverse cardiovascular events after noncardiac surgery. We investigated whether preoperative 12-lead ECGs analysed with deep learning could improve risk prediction. METHODS: In a retrospective cohort of 37 081 adults undergoing major noncardiac surgery (2008-2019, MIMIC-IV database), convolutional neural networks were trained to predict in-hospital myocardial infarction, in-hospital mortality, and a composite of in-hospital myocardial infarction, in-hospital stroke, and 30-day mortality. Models using ECG waveforms alone were compared with fusion models that combined ECGs with 34 routinely collected clinical variables. The primary outcome was discrimination, assessed by the area under the receiver-operating characteristic curve (AUROC) with 10-fold cross-validation and permutation tests vs the RCRI. A generative counterfactual framework provided waveform-level explanations. RESULTS: The fusion model yielded an AUROC=0.858 (95% confidence interval [95% CI], 0.845-0.872) for myocardial infarction, AUROC=0.899 (95% CI, 0.889-0.908) for in-hospital mortality, and AUROC=0.835 (95% CI, 0.827-0.843) for the composite outcome. Fusion model AUROC values exceeded those of ECG-only models (P≤0.002) and the RCRI (myocardial infarction: P=0.001; composite: P<0.001). Counterfactual analysis highlighted prolonged QRS duration, low-voltage complexes, and ST-segment depression as electrophysiologic patterns that consistently correlated with higher predicted risk. CONCLUSIONS: A multimodal deep-learning model that integrates preoperative ECG waveforms with routinely collected clinical data improves prediction of major adverse cardiovascular events, compared with the Revised Cardiac Risk Index. This fully automated approach provides explainable, patient-specific insights, and may improve perioperative risk stratification.
3. Hypertonic saline versus mannitol for brain relaxation in supratentorial tumor surgery: a prospective randomized trial.
In 92 randomized patients undergoing supratentorial tumor surgery, a 3% hypertonic saline strategy improved intraoperative brain relaxation compared with mannitol, and continuous infusion was associated with lower postoperative midline shift and edema. Electrolyte levels were lower with mannitol.
Impact: Addresses a common intraoperative anesthetic-neurosurgical decision with randomized, double-blind evidence suggesting advantages of continuous hypertonic saline over mannitol.
Clinical Implications: For supratentorial tumor cases with mass effect, consider 3% hypertonic saline—particularly continuous infusion—to optimize brain relaxation and reduce postoperative edema/midline shift, while monitoring electrolytes. Effect sizes were modest; centers should align protocols with neurosurgical preferences and patient factors.
Key Findings
- Hypertonic saline bolus improved intraoperative brain relaxation scores vs mannitol (p=0.047; effect size 0.22).
- Continuous hypertonic saline was associated with lower postoperative midline shift and edema compared with other groups (p=0.001 and p=0.006).
- Mannitol group had lower sodium and chloride levels compared to hypertonic saline.
Methodological Strengths
- Prospective, randomized, double-blind design.
- Clinically relevant outcomes including brain relaxation and postoperative imaging indices (midline shift, edema).
Limitations
- Single-center with modest sample size; not powered for neurological outcomes or long-term function.
- Detailed ICP measurements and standardized surgical factors were not reported in the abstract; generalizability may vary.
Future Directions: Multicenter RCTs comparing dosing regimens and monitoring strategies (e.g., ICP-guided therapy), with neurological outcomes and cost analyses.
BACKGROUND: Hypertonic saline and mannitol are widely used to improve brain relaxation during supratentorial mass surgeries. Although continuous administration of hypertonic saline is known to reduce intracranial pressure, it has not yet been evaluated in supratentorial mass surgeries. METHODS: After institutional ethical committee approval, 92 patients scheduled for supratentorial craniotomy with glioblastoma multiforme, metastasis and/or midline shift (> 0.5 cm) were enrolled into this prospective, randomized, and double-blind study. The patients received hypertonic saline 3 mL.kg RESULTS: After randomization, two patients were excluded from the study. Brain relaxation scores were higher with hypertonic saline bolus compared to mannitol (p = 0.047). The effect size between groups for brain relaxation score was 0.22. Hypertonic saline continuous infusion and mannitol were similar with respect to brain relaxation scores. Sodium and chlorine levels were lower in the mannitol group. Postoperative midline shift and edema were lower with continuous hypertonic saline compared to other groups (p = 0.001, p = 0.006). CONCLUSION: Continuous infusion of 3 % hypertonic saline was associated with better relaxation scores in the intraoperative period and with lower incidences of edema/midline shift in the postoperative period of supratentorial mass surgeries with glioblastoma multiforme, metastasis and/or midline shift.